• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Basel Medical Group Ltd

    4/4/25 4:30:11 PM ET
    $BMGL
    Get the next $BMGL alert in real time by email
    6-K 1 form6-k.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of April 2025

     

    Commission File Number: 001-42527

     

    Basel Medical Group Ltd

     

    6 Napier Road,

    Unit #02-10/11 Gleneagles Medical Centre

    Singapore 258499

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒ Form 40-F ☐

     

     

     

     

     

     

    Appointment of Director

     

    On April 4, 2025, the Board of Directors of Basel Medical Group Ltd, a business company incorporated in the British Virgin Islands (the “Company”), appointed Mr. Keng Leong Fung (Raymond Fung) as a director to the Board. Mr. Raymond Fung was nominated to the Board by Rainforest Capital VCC, which is a majority shareholder of the Company. There are no family relationships between Mr. Raymond Fung and any other directors and officers of the Company.

     

    Mr. Fung is the founder of Basel Medical Group Ltd prior to our listing on Nasdaq and serves as our adviser. He has extensive experience in Family Offices, Merger and Acquisition, Capital Market Advisory, Risk & Compliance and Fund Operations. Prior to founding the Basel Medical Group, he started BaselCorp in 2012 as a corporate and financial services firm which was later merged with Incorp Asia. Being a shareholder of the enlarged group, he was in charge of its family offices and financial services. With a portfolio of 15,000 corporate clients across eight countries, Incorp Asia was eventually sold to Hillhouse Capital in 2023. Before establishing BaselCorp, Mr. Fung was a team manager in Citibank in charge of institutional investment funds compliance and trustee operations. He was also a finance lead in the Singapore Ministry of Defence handling defence budget. He started his career as an auditor in a Singapore audit firm.

     

    Mr. Fung served as a non-executive director for various private companies. He was also the advisor and director to various international non-profit organization set up by the Oil and Gas Safety Council and other medical associations. He was also the honorary chairman for Global Chinese Societies Exchange Association.

     

    Mr. Fung holds a Master of Business Administration from Nanyang Business School, Nanyang Technological University of Singapore, and is a member of the Institute of Singapore Chartered Accountants.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Basel Medical Group Ltd  
         
    By: /s/ Raymond Wai Man Cheung  
    Name: Raymond Wai Man Cheung  
    Title: Chief Executive Officer and Director  
         
    Date: April 4, 2025  

     

     

     

     

    Get the next $BMGL alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BMGL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BMGL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Basel Medical Obtains Waiver of Lock-Up for Potential Strategic Fund Raising

      Singapore, June 26, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (NASDAQ:BMGL) (the "Company"), today announced that Cathay Securities, Inc., as the representative of the several underwriters of the Company's initial public offering, has granted its consent on June 23, 2025 to the lock-up provision in the underwriting agreement dated February 24, 2025, permitting (i) a public offering or private placement of new securities of the Company, and (ii) the filing with the U.S. Securities and Exchange Commission of a registration statement under the Securities Act of 1933 in relation to such offering or placement, prior to the expiration of the lock-up period which was due to expire six mont

      6/26/25 4:15:00 PM ET
      $BMGL
    • Basel Medical Group Ltd Reaffirms Strong Financial Position Amid Market Volatility

      Singapore, May 29, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (NASDAQ:BMGL), today reaffirmed the strength of its underlying financial performance and strategic outlook, despite recent volatility in its share price. Speaking on behalf of the Board and management team, BMGL's Chief Executive Officer, Dr Darren Chhoa stated, "While recent movements in our share price may raise questions, I want to assure our shareholders and stakeholders that the fundamentals of BMGL remain strong and resilient. Our financial performance continues to be robust, with our subsidiaries winning new sizable contracts particularly in the supply chain, and we remain on track with our acquisition growth strat

      5/29/25 10:11:00 AM ET
      $BMGL
    • Basel Medical Group Ltd Enters into US$ 1.0 Billion Bitcoin (BTC) Purchase Agreement

      Singapore, May 22, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (NASDAQ:BMGL), today announced that it has entered into a purchase agreement with a consortium of Bitcoin (BTC) holders for the purchase by the Company of up to 10,000 BTC (with current market value of approximately US$1.0 billion) by issuing of its ordinary shares. This purchase will diversify its treasury reserves to a very large extent, while maintaining its core focus on medical services expansion in the Asia Pacific Region. This is a major strategic financial initiative to strengthen the Company's balance sheet and support its aggressive expansion across Asia's high-growth healthcare markets. About Basel Medical Gro

      5/22/25 9:20:00 AM ET
      $BMGL

    $BMGL
    SEC Filings

    See more
    • SEC Form 6-K filed by Basel Medical Group Ltd

      6-K - Basel Medical Group Ltd (0002004489) (Filer)

      7/1/25 8:01:42 PM ET
      $BMGL
    • SEC Form 6-K filed by Basel Medical Group Ltd

      6-K - Basel Medical Group Ltd (0002004489) (Filer)

      6/26/25 4:20:32 PM ET
      $BMGL
    • SEC Form 6-K filed by Basel Medical Group Ltd

      6-K - Basel Medical Group Ltd (0002004489) (Filer)

      6/18/25 6:30:24 AM ET
      $BMGL